EA201791714A1 - Профилактика или лечение мочекислых или подагрических заболеваний - Google Patents

Профилактика или лечение мочекислых или подагрических заболеваний

Info

Publication number
EA201791714A1
EA201791714A1 EA201791714A EA201791714A EA201791714A1 EA 201791714 A1 EA201791714 A1 EA 201791714A1 EA 201791714 A EA201791714 A EA 201791714A EA 201791714 A EA201791714 A EA 201791714A EA 201791714 A1 EA201791714 A1 EA 201791714A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
diseases
uric acid
subgregation
Prior art date
Application number
EA201791714A
Other languages
English (en)
Other versions
EA034139B1 (ru
Inventor
Цянь Чжан
Чжэньхуа Хуан
Цзиньжон Лю
Шуаншуан Чи
Original Assignee
Шаньтонь Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шаньтонь Фарма Ко., Лтд. filed Critical Шаньтонь Фарма Ко., Лтд.
Publication of EA201791714A1 publication Critical patent/EA201791714A1/ru
Publication of EA034139B1 publication Critical patent/EA034139B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к применению соединения формулы (I), его фармацевтически приемлемой соли, его сольвата или содержащей его фармацевтической композиции для снижения уровня мочевой кислоты, профилактики или снижения воспаления и профилактики или лечения мочекислых или подагрических заболеваний. В частности, данное изобретение относится к применению соединения формулы (I), его фармацевтически приемлемой соли, его сольвата или содержащей его фармацевтической композиции для производства лекарственного средства для лечения или профилактики гиперурикемии, подагры, подагрических воспалений, боли и мочекислой нефропатии:где Rявляется водородом, Cалкилом или подобным, Rявляется Cалкилом или подобным, Rявляется галогеном или подобным.
EA201791714A 2015-01-30 2016-01-28 Профилактика или лечение мочекислых или подагрических заболеваний EA034139B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510048096 2015-01-30
CN201510079809 2015-02-13
CN201510080714 2015-02-13
CN201510216089 2015-04-30
PCT/CN2016/000061 WO2016119570A1 (zh) 2015-01-30 2016-01-28 尿酸性或痛风性疾病的预防或治疗

Publications (2)

Publication Number Publication Date
EA201791714A1 true EA201791714A1 (ru) 2017-11-30
EA034139B1 EA034139B1 (ru) 2020-01-09

Family

ID=56542370

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791714A EA034139B1 (ru) 2015-01-30 2016-01-28 Профилактика или лечение мочекислых или подагрических заболеваний

Country Status (26)

Country Link
US (1) US10322132B2 (ru)
EP (1) EP3251675B1 (ru)
JP (1) JP6678685B2 (ru)
KR (1) KR102128810B1 (ru)
CN (1) CN107206002B (ru)
AU (1) AU2016212625B2 (ru)
BR (1) BR112017016065A2 (ru)
CA (1) CA2973746C (ru)
CY (1) CY1124383T1 (ru)
DK (1) DK3251675T3 (ru)
EA (1) EA034139B1 (ru)
ES (1) ES2881872T3 (ru)
HK (2) HK1244434A1 (ru)
HR (1) HRP20211007T1 (ru)
HU (1) HUE054741T2 (ru)
IL (1) IL253726B2 (ru)
LT (1) LT3251675T (ru)
MA (1) MA41431B1 (ru)
MX (1) MX2017009853A (ru)
PL (1) PL3251675T3 (ru)
PT (1) PT3251675T (ru)
SG (2) SG11201705889VA (ru)
SI (1) SI3251675T1 (ru)
TW (1) TWI680761B (ru)
WO (1) WO2016119570A1 (ru)
ZA (1) ZA201704600B (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
PL1781657T3 (pl) * 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
CN101479273B (zh) * 2006-06-23 2011-11-30 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
ATE486874T1 (de) * 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20110136835A1 (en) 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia

Also Published As

Publication number Publication date
TW201628623A (zh) 2016-08-16
KR102128810B1 (ko) 2020-07-02
JP2018503691A (ja) 2018-02-08
DK3251675T3 (da) 2021-06-28
WO2016119570A1 (zh) 2016-08-04
MX2017009853A (es) 2017-11-01
TWI680761B (zh) 2020-01-01
PL3251675T3 (pl) 2021-11-02
IL253726A0 (en) 2017-09-28
EA034139B1 (ru) 2020-01-09
EP3251675A1 (en) 2017-12-06
ZA201704600B (en) 2020-07-29
PT3251675T (pt) 2021-05-25
BR112017016065A2 (pt) 2018-04-03
HK1244434A1 (zh) 2018-08-10
ES2881872T3 (es) 2021-11-30
CA2973746A1 (en) 2016-08-04
US10322132B2 (en) 2019-06-18
KR20170106485A (ko) 2017-09-20
LT3251675T (lt) 2021-07-12
MA41431B1 (fr) 2021-05-31
HK1245146A1 (zh) 2018-08-24
CN107206002B (zh) 2019-07-16
CA2973746C (en) 2020-03-24
SG11201705889VA (en) 2017-08-30
HRP20211007T1 (hr) 2021-09-17
US20170326148A1 (en) 2017-11-16
HUE054741T2 (hu) 2021-09-28
CY1124383T1 (el) 2022-07-22
JP6678685B2 (ja) 2020-04-08
IL253726B1 (en) 2023-03-01
EP3251675B1 (en) 2021-04-21
IL253726B2 (en) 2023-07-01
SG10201907026RA (en) 2019-09-27
AU2016212625B2 (en) 2020-03-26
SI3251675T1 (sl) 2021-08-31
AU2016212625A1 (en) 2017-07-27
MA41431A (fr) 2017-12-06
EP3251675A4 (en) 2018-06-20
CN107206002A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
NZ708593A (en) Novel pyrazole derivative
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201790088A1 (ru) Ингибиторы syk
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
MY195675A (en) A Group of Compounds used for the Treatment or Prevention of Hyperuricemia or Gout
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
IN2015MN00045A (ru)

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment